How Much Does Oral Micronized Progesterone Cost in Virginia in 2026?

Virginia Pricing Breakdown: Brand, Generic, and Compounded

The price you pay for oral micronized progesterone in Virginia depends almost entirely on which version you fill. Brand-name Prometrium, originally developed by Solvay Pharmaceuticals (now part of AbbVie), carries a manufacturer list price near $180 per month for a 30-capsule supply of 100 mg or 200 mg capsules [1]. Very few patients pay that number out of pocket.

Generic micronized progesterone capsules, manufactured by companies including Teva and Sun Pharma, average $45 per month across Virginia retail pharmacies in 2026. Prices vary by pharmacy. A Costco or independent pharmacy in Richmond or Norfolk may quote $30 to $38, while a CVS or Walgreens in Northern Virginia could quote $50 to $55 for the same drug and quantity. Calling multiple pharmacies before filling is worth the five minutes.

Compounded oral micronized progesterone from a licensed 503A compounding pharmacy in Virginia typically costs around $25 per month. The 503A designation, defined under Section 503A of the Federal Food, Drug, and Cosmetic Act, allows pharmacies to compound medications based on individual prescriptions from licensed practitioners. Virginia permits 503A compounding, and multiple pharmacies in the Hampton Roads, Richmond, and Northern Virginia corridors offer compounded progesterone capsules or troches.

The FDA-approved labeling for Prometrium specifies its use for prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens [2]. This indication matters for insurance coverage determinations, as most payers require documentation of concurrent estrogen therapy for approval.

Virginia Medicaid Coverage and Prior Authorization

Virginia Medicaid covers oral micronized progesterone, but the program requires prior authorization before dispensing [3]. That PA process is not optional. Without it, the pharmacy claim rejects at the point of sale.

The prior authorization criteria typically require the prescriber to document that the patient is receiving estrogen replacement therapy and needs endometrial protection, or that the progesterone is prescribed for another covered indication such as secondary amenorrhea. The PEPI trial (Postmenopausal Estrogen/Progestin Interventions), published in JAMA in 1995 with 875 women enrolled, established that oral micronized progesterone at 200 mg per day for 12 days per cycle effectively opposed estrogen-stimulated endometrial hyperplasia while producing a more favorable lipid profile than medroxyprogesterone acetate [4]. That trial remains a foundational reference in formulary committee decisions about progesterone coverage.

Virginia Medicaid managed care organizations, including Aetna Better Health of Virginia, Anthem HealthKeepers, Molina Healthcare of Virginia, and Virginia Premier, each manage their own formulary tiering and PA criteria. Some MCOs place generic micronized progesterone on Tier 2 (preferred generic), while others require a Tier 3 PA. Your prescriber's office should submit the PA. Expect 24 to 72 hours for a decision.

For patients who are denied, Virginia Medicaid allows a standard appeal with supporting clinical documentation. Including the PEPI trial citation and the patient's estrogen prescription in the appeal letter improves approval rates based on prescriber reports.

Commercial Insurance Coverage Across Virginia

Most commercial insurance plans available in Virginia cover generic oral micronized progesterone. The question is where it sits on the formulary tier. Plans sold through the Virginia Health Benefit Exchange (the ACA marketplace) and employer-sponsored plans from Anthem, Cigna, Aetna, UnitedHealthcare, and Kaiser Permanente (in the Northern Virginia service area) generally place generic micronized progesterone on Tier 1 or Tier 2 with copays ranging from $0 to $25 per month.

Brand Prometrium faces heavier restrictions. Most commercial formularies classify it as non-preferred brand (Tier 3) or exclude it entirely, requiring step therapy through the generic first. A few plans still cover brand Prometrium with a $40 to $75 copay when generic intolerance is documented. The most common reason for generic intolerance: the peanut oil in some generic formulations triggers allergies.

Both the brand and several generic micronized progesterone capsules contain peanut oil as an inactive ingredient, since the progesterone is dissolved in peanut oil inside the gelatin capsule [2]. Patients with documented peanut allergy may need compounded progesterone in a different oil base (typically olive oil or sunflower oil), which creates a legitimate clinical rationale for the 503A compounded product even when insurance would otherwise prefer the manufactured generic.

Federal Employee Health Benefits (FEHB) plans, which cover a substantial workforce in Northern Virginia near the Pentagon, Fort Belvoir, and Quantico, typically cover generic micronized progesterone with standard copays. TRICARE also covers it as a Tier 1 generic at military pharmacies ($0 copay) and through retail network pharmacies (copay varies by plan tier).

Compounded Progesterone in Virginia: Legal Status and Practical Details

Compounded progesterone is legal in Virginia through licensed 503A pharmacies. Virginia law does not prohibit the compounding of commercially available drugs when a prescriber writes a prescription specifying compounding, though some insurers will not cover compounded medications when an FDA-approved equivalent exists.

The distinction between 503A and 503B compounding matters. A 503A pharmacy compounds patient-specific prescriptions. A 503B outsourcing facility, registered with the FDA under Section 503B, can produce larger batches without patient-specific prescriptions and is subject to FDA current good manufacturing practice (cGMP) requirements. Both operate in Virginia, but the typical patient filling a monthly progesterone prescription uses a 503A pharmacy.

Compounded progesterone runs approximately $25 per month at Virginia 503A pharmacies for a 30-day supply of 100 mg or 200 mg capsules. Prices at compounding pharmacies are generally fixed and transparent because compounded medications rarely process through insurance. Some compounding pharmacies in Virginia also offer progesterone in sublingual troche, topical cream, or vaginal suppository forms at similar price points, though oral capsules remain the most commonly prescribed form for endometrial protection.

The Virginia Board of Pharmacy regulates compounding pharmacies under 18 VAC 110-20 and requires compliance with United States Pharmacopeia (USP) chapters 795 (nonsterile) and 797 (sterile) standards. Patients should verify that their compounding pharmacy holds an active Virginia Board of Pharmacy license.

Telehealth Prescribing: Getting Progesterone Without an In-Person Visit

Virginia permits telehealth prescribing of oral micronized progesterone. No in-person visit is required for the initial prescription or refills, provided the prescriber establishes a valid patient-provider relationship through the telehealth encounter.

Virginia's telehealth parity law, codified under Va. Code § 38.2-3418.16, requires insurers to cover telehealth-delivered services at the same reimbursement rate as in-person services. This means the prescriber visit itself should be covered at the same copay whether conducted by video, phone (for established patients), or in the office.

Telehealth platforms operating in Virginia, including HealthRX, can prescribe oral micronized progesterone and send the prescription to any Virginia-licensed pharmacy, including 503A compounding pharmacies. The prescription is transmitted electronically through standard e-prescribing systems. Controlled substance restrictions do not apply because progesterone is not a scheduled controlled substance under federal or Virginia law.

A practical advantage of telehealth for progesterone prescriptions: lab review. Prescribers typically want to review a recent progesterone level, FSH, estradiol, and possibly a lipid panel before initiating or adjusting HRT. Telehealth allows the prescriber to order labs at a Quest or Labcorp draw site near the patient, review results asynchronously, and then conduct the prescribing visit by video. Total time from lab order to filled prescription can be under one week.

How to Get the Lowest Price in Virginia

The cheapest path to oral micronized progesterone in Virginia depends on your coverage situation.

If you have commercial insurance or FEHB: Fill the generic at your plan's preferred pharmacy. Most patients pay $0 to $25 per month. Check your formulary to confirm the generic is Tier 1 or Tier 2.

If you have Virginia Medicaid: Ask your prescriber's office to submit the prior authorization before the first fill. Generic micronized progesterone is covered once PA is approved. Your copay will be $0 to $4 depending on your Medicaid MCO and income level.

If you are uninsured or underinsured: Compare three options. First, check GoodRx, RxSaver, or the manufacturer savings card for generic pricing at retail pharmacies. These discount tools frequently bring the price to $30 to $40 for a 30-day supply. Second, call a local 503A compounding pharmacy for a quote on compounded progesterone capsules. At roughly $25 per month, this is often the cheapest option. Third, consider Mark Cuban's Cost Plus Drugs (costplusdrugs.com), which offers generic micronized progesterone with transparent markup pricing and ships to Virginia addresses.

Manufacturer savings cards for Prometrium (brand) exist but are most useful for patients whose insurance covers brand-name drugs with a high copay. The card typically reduces the copay to $25 to $50 for a 30-day supply. These cards do not work with Medicaid, Medicare Part D, or other government-funded programs per federal anti-kickback statute requirements.

The Endocrine Society's 2022 clinical practice guideline on hormone therapy in menopause recommends micronized progesterone over synthetic progestins for most patients based on the cardiovascular and breast safety signals from observational data, including the E3N French cohort study (N=80,377) which found that women using micronized progesterone had no significant increase in breast cancer risk compared to estrogen alone over a mean follow-up of 8.1 years [5][6]. That guideline preference has helped keep micronized progesterone on most formularies.

Virginia-Specific Considerations for 2026

Two Virginia-specific factors affect progesterone access in 2026. First, Virginia expanded Medicaid under the ACA in 2019, and the program now covers approximately 2 million residents. The Medicaid expansion population (adults aged 19 to 64 with household income up to 138% of the federal poverty level) has access to oral micronized progesterone through the PA pathway described above.

Second, Virginia's 2024 legislative session included updates to pharmacy benefit manager (PBM) transparency requirements. These PBM reforms, effective January 2025, require PBMs operating in Virginia to report spread pricing and rebate pass-through rates to the Virginia Bureau of Insurance. While this does not directly change the price of progesterone at the counter, it increases transparency in how pharmacy reimbursement is calculated and may reduce patient costs over time as payers compete on pass-through rebate models.

For patients near the Virginia-DC-Maryland border (a large population in Northern Virginia), filling prescriptions in DC or Maryland may sometimes yield different pricing due to different state dispensing fees and Medicaid formulary structures. However, for most patients, the difference is marginal for a low-cost generic.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on hormone therapy (reaffirmed 2024) states: "Micronized progesterone is preferred over medroxyprogesterone acetate for endometrial protection in women taking estrogen therapy, based on a more favorable side-effect profile and preliminary evidence of lower breast cancer risk" [7]. This recommendation supports formulary coverage and PA approvals across Virginia payers.